Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
NCT03491215
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
45
Enrollment
INDUSTRY
Sponsor class
Conditions
Acute Graft Versus Host Disease
Interventions
DRUG:
Ruxolitinib
Sponsor
Novartis Pharmaceuticals